Researchers led by Université de Montréal pathology and cell-biology professor Marc Therrien have identified major structural ...

A research team has developed a new class of compounds that effectively inhibit both wild-type CDK9 and its drug-resistant ...

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; Inhibition rate of ~90% observed in GP2D human colorectal cancer cells; ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

A study has uncovered a surprising link between diet, intestinal microbes and the efficacy of cancer therapy. A Ludwig Cancer Research study has uncovered a surprising link between diet, intestinal ...

A Ludwig Cancer Research study has uncovered a surprising link between diet, intestinal microbes and the efficacy of cancer ...

The researchers applied a CDK7-inhibitor provided by Syros Pharmaceuticals ... to a universal mechanism by which CDK7 controls human cell proliferation, said Taatjes. "We found that the second ...

Nonetheless, clinical studies with both inhibitors of IL-1 and TNF have shown beneficial effects on radiographic progression in RA. IL-1 was the first proinflammatory cytokine to be identified and ...

Impact of immune-related adverse events (irAE) onset on disease response and survival in patients (pts) with head-neck cancer treated with immune check point inhibitors (ICI). This is an ASCO Meeting ...

Department of Medicinal Chemistry, Key Laboratory of Chemical Biology (MOE), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012, China ...